VitalStrategic States Growing Attention on Real World Evidence in China

Berwyn, Pennsylvania, UNITED STATES

BERWYN, Pa., May 6, 2013 (GLOBE NEWSWIRE) -- VitalStrategic Research Institute, ("VSRI"), a leading research firm in clinical and outcomes research announced today that the 2013 China Outcomes Research and Evidence Based Medicine ("CORE") Summit was successfully held last month in Shanghai, China. CORE is an international conference that VSRI co-organizes with Chinese Medical Doctor Association. Since its inaugural event in 2011, CORE Summit has attracted an increasing number of experts, speakers and delegates from both inside and outside of China each year, and has become one of the most important events in promoting evidence based medicine in China.

After nearly two decades of persistent efforts and the implementation of strengthened regulations by the SFDA, streams of novel medical products have been introduced into the China market, resulting in the increased demand for real world comparative evidence in clinical and cost effectiveness of medical interventions.

"CORE creates a platform where stakeholders from government, medical society, and industry could conjoin their vision, policy, evidence, and thereby stimulating and reinforcing the practice of evidence based medicine," stated Dr. Danyi Zhang, President and Chief Medical Officer of VSRI and Chairman of CORE Summit. At this year's conference, Director of AHRQ, Carolyn Clancy, MD, Director of Epidemiology of FDA, Danica Marinac-Dabic, MD, Senior Executive Editor of The Lancet, William Summerskill, MD, President of Joslin Diabetes Center of Harvard Medical School, Mr. John Brooks, as well as Chinese academic leaders, including Dr. Gordon Liu, Director of Center for Health Economics Peking University, Dr. Zhijie Zheng, Dean of Public Health, Jiaotong University, and Dr. Guangjun Yu, President of Shanghai Children Hospital, were among the nearly thirty distinguished speakers. There was clearly increased interest in topics including health economics and real world evidence, social insurance, pricing policy, health reform, as well as electronic medical records.

Patient registry was one of the big topics this year. The discussion was augmented by the introduction of NCDR (National Cardiovascular Data Registry) organized by American College of Cardiology, and the CCMR (China Cardiometabolic Registries) organized by Chinese Medical Doctor Association and VitalStrategic Research Institute. NCDR and CCMR represent the largest registry series in the US and China in the cardiovascular and metabolic disease areas, respectively.

The multi-national pharmaceutical and medical device industry have been playing critical roles at CORE Summit. Senior executives including Drs. Tehseen Salimi and Quanwu Zhang of Sanofi, Dr. Hong Li of Bristol Myers Squibb, Mr. David Grainger of Eli Lilly, Dr. Jing Xie of Biomet and prior Sanofi executive Dr. Jean-Pierre Lehner all spoke at the conference; other pharma companies including Pfizer, Bayer, Abbott, Merck, and organizations in the field of outcomes research and health economics, including IMS Health, Quintiles Outcome, Analysis Group, and Aldelphi were all well represented.

"CORE has a progressive theme each year," Dr. Zhang added, "The 2014 CORE Summit will place more weight on the topics including eHealth, eClinical and the practice of using electronic medical records for measuring clinical outcomes, healthcare quality and patient engagement."

More information about the CORE Summit is available at:

About VitalStrategic Research Institute

VSRI is a leader in clinical research, outcomes research, health informatics, and health economics that operates in the US and China. Through conducting nationwide registries, VSRI has developed a network of over 500 hospitals and clinics in China where its EDC/EMR system is implemented. VSRI has a strong collaborative relationship with Chinese Medical Doctor Association who has a reach to nearly 2 million physicians. More information about VSRI is at: and


Contact Data